Advanced searches left 3/3

Treatment Side effect - Europe PMC

Summarized by Plex Scholar
Last Updated: 27 July 2022

* If you want to update the article please login/register

Patient, provider, and nurse preferences of patient reported outcomes (PRO) and side effect management during cancer treatment of underrepresented racial and ethnic minority groups, rural and economically disadvantaged patients: a mixed methods study.

Purpose The purpose of this research was to examine patient, oncologist, and nurse perspectives on side effects and patient reported outcomes, as well as the challenge of how to properly utilize side effect management and PRO tools in this particular population. Patients receiving intravenous chemotherapy from June to August 2020 were surveyed regarding side effect prevalence and PRO system preferences. All patients reported having access to a cell phone, but 12. 2% did not own one; 68% smart phone, 22% cell phone, 22% landline, and 39% tablet. Patients preferred a response to reported side effects within 0-3 h, whereas only 29% of the 55 PN surveyed did not. Interviews confirmed that side effect burden was a significant issue, because of the various communication technologies, and a PRO system could help with side effect control. Although most agreed that side effect management was a significant topic, patient and PN's expectations differed sharply.

Source link: https://europepmc.org/article/MED/35829828


Duodenal Necrosis and Nonvariceal Digestive Bleeding After Terlipressin Administration for Treatment of Hepatorenal Syndrome: a Case Report of a Novel Side Effect of a Commonly Used Drug.

Terlipressin is a drug used in cirrhotic patients to treat hepatorenal syndrome and vaginal bleeding. This is a case report of a cirrhotic patient with nonvariceal upper gastrointestinal bleeding after duodenal necrosis due to the use of terlipressin, a novel side effect that has yet to be described in literature to our knowledge. Case study The 51-year-old male patient with alcohol liver cirrhosis and hepatitis C virus infection was found to have oliguria associated with severe ascites and lower leg edema. His End Stage Liver Disease-Sodium test was 19 years old, and his serum creatine level was 2. 12 mg/dL. In continuous infusion, Terlipressin infusion was initiated, and serum creatinine levels gradually decreased, and Terlipressin infusion was started, and Terlipressin infusion was initiated. After 7 days, the patient suffered hemorrhagic shock secondary to hematemesis. We reviewed a case of nonvariable upper gastrointestinal bleeding secondary to duodenal necrosis, which was triggered by visceral ischemia induced by terlipressin.

Source link: https://europepmc.org/article/MED/35676183


The growing role of rucaparib in contemporary treatment of metastatic prostate cancer: a review of efficacy and guidance for side effect management.

Physicians have now been advised that physicians must be aware of the role and nuances of PARP inhibitor therapy for prostate cancer management. Expert opinion We believe that the time has come to develop functional assays of HRR capability or deficiency in order to help guide PARP inhibitor selection for patients with prostate cancer and beyond.

Source link: https://europepmc.org/article/MED/35594523


Late Onset of ANCA Vasculitis as a Side Effect of Levamisole Treatment in Nephrotic Syndrome.

Levamisole is well tolerated in steroid-dependent nephrotic syndrome, and the most common side effects reported are cytopenia and liver enzyme changes. Since the start of the therapy, a four-year-old boy who was affected by steroid-dependent nephrotic syndrome was treated with Levamisole as a steroid-sparing agent in a dose of 2 mg/kg/48 h, resulting in a dramatic decrease in the cumulative steroid dose. Since the symptoms began two days after the injection of the second dose of the COVID-19 vaccine, it was immediately determined that these manifestations were unusual vaccination side effects. We want to raise concerns among clinicians about a rare complication of Levamisole therapy that is often misdiagnosed due to the fact that there are no univocal recommendations regarding the precise timing of ANCA titrations and treatment durations.

Source link: https://europepmc.org/article/MED/35630067


Communication, perception, and use of personalized side-effect risks in prostate cancer treatment-decision making: An observational and interview study.

Objective We investigated how healthcare professionals communicate personalized risks of treatment side-effects to patients with localized prostate cancer during consultations, as well as how these patients perceive and use such risks during treatment decision-making. Patients can help patients understand and recall their risk factors and personalized risk estimates by clearly identifying the connection between risk factors and personalized risk estimates. HPs should not only provide patients specific and detailed numerical risk data, but also put in an effort to clarify how the personalized side-effect risks are determined.

Source link: https://europepmc.org/article/MED/35534301

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions